MORRISTOWN, N.J., Aug. 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE: WPI) today announced that Robert Stewart, who joined the Company in November 2009 as Senior Vice President, Global Operations, has been promoted to Executive Vice President, Global Operations. Mr. Stewart will continue to report to Paul Bisaro, President and Chief Executive Officer of Watson.
Mr. Stewart will assume responsibility for managing Global Generic Research and Development activities, in addition to having responsibility for Global Operations (manufacturing, supply chain, engineering, facilities and EH&S), Global Quality and Regulatory and Global Information Technology.
"This promotion recognizes the contributions Bob and his team have made in integrating the assets, technologies and resources acquired from Arrow and in continuing to maximize the potential of our global supply chain," said Bisaro. "As a result of this promotion, the three significant components of our business -- Global Generics, Global Brands and Global Operations -- will now be led by Executive Vice Presidents, reporting directly to me. In addition, moving Generic R&D under Global Operations recognizes that close coordination between R&D and Operations is critical to accelerating speed to market. Bob will now assume responsibility for ensuring that the process from product development to approval and distribution is seamless and efficient, enhancing our ability to compete in the markets we serve with products that create increased value for our customers and our shareholders."
Mr. Stewart joined Watson following an eight-year career at Abbott Laboratories, where he most recently served as Divisional Vice President, Global Supply Chain. From 2005 until 2008, he served as Divisional Vice President, Quality Assurance. Prior to this position, Mr. Stewart was Abbott's Divisional Vice President for U.S./Puerto Rico and Latin America Plant Operations, as well as Director of Operations for Abbott's Whippany, NJ plant. Prior to Abbott, he worked for Knoll Pharmaceutical Company and Hoffman La-Roche Inc.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on urology and women's health. Watson has operations in many of the world's established and growing international markets.
For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.
Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, such risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2009 and Watson's quarterly report on Form 10-Q for the period ended March 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.
|SOURCE Watson Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved